CXCL13 and neoplasm: In pancreatic cancer, neoadjuvant chemotherapy reversed the PD‐L1/PD‐1‐mediated inhibition of Tfh cells, enabling CXCL13‐mediated recruitment of B cells and IL‐21‐driven differentiation of PCs, ultimately enhancing anti‐tumour immunity.101